Bio-Thera Solutions, Ltd

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. The company offers QLETLI for treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, and metastatic cervical cancer; and BAT1806 for the treatment of rheumatoid arthritis, systemicjuvenile idiopathic arthritis, and cytokine release syndrome. It also develops BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn's disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406F, BAT6026, BAT2606, and BAT2506 for treatment of various autoimmune diseases. In addition, the company develops BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT6005, BAT6021, BAT7104, BAT8006, BAT8009, BAT8010, BAT8008, and BAT8007 for treatment of oncology; BAT2094 and BAT6024 to treat cardiovascular diseases; BAT5906 that is in Phase III clinical trial for the treatment for wet age-related macular degeneration (wAMD) and Phase II clinical trial for the treatment for diabetic macular edema (DME); and BAT2022 to treat respiratory infectious diseases. Bio-Thera Solutions, Ltd. was founded in 2003 and is headquartered in Guangzhou, China.